Boston Scientific Announces Scheduled Presentations At TCT 2015
Clinical and Economic Data to be Presented at World's Leading Interventional Cardiology Meeting

MARLBOROUGH, Mass., Oct. 7, 2015 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced key data presentations spanning its broad interventional cardiology, structural heart and peripheral interventions portfolios to be shared at the 27th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation, to be held in San Francisco October 11-15.

Scheduled abstracts will evaluate Boston Scientific technologies for treating patients with a range of cardiovascular diseases, and explore topics including:

  • The costs associated with bleeding complications due to warfarin versus the WATCHMAN™ Left Atrial Appendage Closure Device, which was approved by the U.S. Food and Drug Administration (FDA) in March, 2015 to reduce the risk of stroke in people with non-valvular atrial fibrillation;
  • Lotus™ Transcatheter Aortic Valve Implantation (TAVI) System safety and efficacy data from the REPRISE I and REPRISE II studies; and
  • Long-term safety and efficacy data out to five years with the PROMUS Element® Platinum Chromium Everolimus-Eluting Stent.

Earlier this week, the company received FDA approval of the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of patients with coronary artery disease (CAD). The commercialization of the first and only BP-DES in the U.S. reinforces the depth and breadth of the Boston Scientific innovative cardiology portfolio. 

"The recently approved and first-to-market WATCHMAN Device and SYNERGY Stent are opening doors for cardiologists to treat patients with non-valvular atrial fibrillation and coronary artery disease in new and innovative ways," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "In addition to exploring these prevalent health conditions at TCT, we will also share data crucial to the advancement of device-related treatment for patients suffering from aortic valve disease and peripheral arterial disease."

ABSTRACTS OF INTEREST (listed chronologically within product categories)

Coronary Stents

  • Everolimus-Eluting Bioabsorbable-Polymer DES Outcomes: SYNERGY Update: Dean Kereiakes, M.D., will lead a discussion on the SYNERGY Stent during the Metallic Drug-Eluting Stents: Controversies with Today's Technology Symposium on Sunday, October 11 from 1:05-1:13 p.m. in Moscone West, 3rd Floor, Rooms 3001-3005.
  • Two-Year Outcomes in 'Real-World Patients' Treated with a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent, in the PROMUS Element Plus US Post-Approval Study (PE-Plus PAS): David Kandzari, M.D., will present on Tuesday, October 13 at 3:30 p.m. in Rooms 3014-3018.
  • Final 5-Year Outcomes Following Implantation of the PROMUS Element Platinum Chromium Everolimus-Eluting Stent in De Novo Coronary Artery Lesions in Small Vessels (SV) and Long Lesions (LL): Results of the PLATINUM Small Vessel and Long Lesion trials: Paul Teirstein, M.D., will present during the poster session on Tuesday, October 13 from 4 -6 p.m. in the Poster Hall (West Building).


  • Cost Analysis of Bleed Complications from Two Stroke Prevention Strategies in Non-Valvular Atrial Fibrillation: Left Atrial Appendage: Matthew Price, M.D., will present on Tuesday, October 13 at 3:30 p.m. Check final TCT agenda for presentation location.

Structural Heart

  • First Report of Three-Year Outcomes with the Repositionable and Fully Retrievable Lotus Aortic Valve Replacement System: Results from the REPRISE I Feasibility Study: Prof. Ian Meredith, Ph.D., will present during the poster session on Tuesday, October 13 from 4-6 p.m. in the Poster Hall (West Building).
  • Two-Year Outcomes with the Fully Repositionable and Retrievable Lotus™ Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients with Severe Aortic Stenosis: Results from the REPRISE II CE-Mark Study: Prof. Ian Meredith, Ph.D., will present on Thursday, October 15 at 12:45 p.m. in Room Moscone South, Lower Level, Room 104.

Peripheral Interventions

  • Bipolar Radiofrequency Renal Denervation with the Vessix Catheter in Patients with Resistant Hypertension: 2-year Results from the REDUCE-HTN trial: Prof. Horst Sievert, M.D., Ph.D., will present during the poster session on Tuesday, October 13, 2015 from 4 -6 p.m. in the Poster Hall (West Building).

All programs are listed in Pacific Daylight Time and will take place at the Moscone Convention Center unless otherwise noted. For additional product information, visit Boston Scientific at booth #1225.

Lotus is an investigational device and not available for sale in the U.S.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit and connect on Twitter and Facebook.

Trish Backes
Boston Scientific Corporation
651-582-5887 (office)

Susie Lisa, CFA
Boston Scientific Corporation
(508) 683-5565 (office)

SOURCE Boston Scientific Corporation